Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $54.64

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve ratings firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $54.64.

Several analysts have recently commented on the stock. Guggenheim raised their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Wedbush restated an "outperform" rating and set a $42.00 price objective on shares of AnaptysBio in a report on Thursday. Truist Financial increased their target price on AnaptysBio from $20.00 to $30.00 and gave the stock a "hold" rating in a report on Thursday, August 15th. UBS Group boosted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a research note on Wednesday, October 30th. Finally, HC Wainwright lowered their price objective on AnaptysBio from $55.00 to $52.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th.

AnaptysBio Stock Performance

Shares of NASDAQ:ANAB traded down $1.17 during midday trading on Friday, hitting $19.00. 628,757 shares of the stock were exchanged, compared to its average volume of 598,903. The business's 50-day moving average price is $31.06 and its 200 day moving average price is $29.91. AnaptysBio has a 12 month low of $13.36 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating analysts' consensus estimates of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to analysts' expectations of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. Equities research analysts anticipate that AnaptysBio will post -6.02 earnings per share for the current year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the transaction, the insider now directly owns 15,398 shares of the company's stock, valued at approximately $595,440.66. This represents a 8.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Dennis Mulroy sold 12,220 shares of the company's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at $189,333.04. This represents a 72.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock worth $892,936 in the last ninety days. Company insiders own 33.70% of the company's stock.

Institutional Investors Weigh In On AnaptysBio

Institutional investors and hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC purchased a new stake in AnaptysBio during the first quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of AnaptysBio during the 1st quarter valued at about $265,000. Acadian Asset Management LLC bought a new stake in AnaptysBio in the 1st quarter worth approximately $420,000. Platinum Investment Management Ltd. purchased a new stake in AnaptysBio in the first quarter worth approximately $1,490,000. Finally, StemPoint Capital LP grew its position in AnaptysBio by 499.0% during the first quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company's stock valued at $6,070,000 after acquiring an additional 224,548 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.